Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

NCT00122304 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemoglobinuria, Paroxysmal

Interventions

DRUG: eculizumab

Sponsor

Alexion Pharmaceuticals, Inc.